Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer
Latest Information Update: 19 Mar 2019
At a glance
- Drugs Nirogacestat (Primary) ; Docetaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 02 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 16 Jul 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 16 Jul 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.